DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for skin disease — screening already-approved drugs against its 43-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSkin disease maps to a 43-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedRuxolitinibApproved drug
Structures already discussed alongside skin disease in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Human JAK2 JH1 domain — Ruxolitinib has a real, experimentally solved structure in complex with this target (PDB 6WTN, 1.83 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet rxtdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6WTN · 1.83 Å · ligand Ruxolitinib (RXT). Experimental structure, not a prediction.
What the evidence adds up to
A 2021 review of skin disease in sub-Saharan Africa found the condition of disease to be at a dangerous level, with many treatment options unavailable in rural areas. The review called for more research to develop a better understanding of the disease and its treatment, but provided no specific data on prevalence, survival, or response to any therapy.
A 2019 scoping review of 69 studies examined psychosocial adaptation in skin disease patients. It identified demographic, disease-related, psychological, and social factors that influence adaptation, including anxiety, depression, stigma, and suicidal ideation. A limited number of studies found benefit from cognitive behavioural training, educational training, and self-help programmes as adjuvant care. The review did not report effect sizes or sample sizes for any intervention.
A 2022 review of ruxolitinib 1.5% cream for atopic dermatitis stated it was the first FDA-approved topical JAK inhibitor and reported high efficacy and a favourable safety profile. The review did not provide numerical response rates, survival data, or sample sizes from the underlying trials.
The evidence base for skin disease treatment in sub-Saharan Africa remains a literature review without trial data. The psychosocial adaptation review lacks quantitative outcomes for the interventions it describes. The ruxolitinib review, while positive, omits the concrete numbers needed to assess its claims. What is missing are adequately funded randomised controlled trials in sub-Saharan African populations, standardised psychosocial outcome measures, and transparent reporting of response rates and adverse events for topical JAK inhibitors.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Infectious Disorders - Drug Targets · 2021 · 20 citations
Skin Diseases and their Treatment Strategies in Sub-Saharan AfricanRegions
AbstractBACKGROUND: In the rural areas of sub-Saharan African regions, skin diseases are so common. Due to which the population of the sub-Saharan region suffers from different types of skin disorders. In these regions, many treatment options are not available for the treatment of skin disease. AIM: The current study aims to discuss various skin diseases and their treatment strategies, specifically in sub-Saharan African regions. METHODS: Extensive literature survey was carried out by using Scopus, Science Direct, Elsevier, Google scholar and Bentham science databases. RESULTS AND DISCUSSION: It was demonstrated from the literature surveys that different effective techniques are used in the management of skin disease. In the result, it was shown that the condition of the disease is at a dangerous level which must be controlled. CONCLUSION: It is concluded from the manuscript that the skin disorder in the sub-Saharan region is at a very dangerous level. The research must be done to develop a better understanding of the disease and its treatment.
Journal of Asthma and Allergy · 2022 · 13 citations · open access
Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
AbstractAtopic dermatitis (AD) is a common chronic, pruritic inflammatory skin disease that profoundly impacts patients' quality of life. As the first FDA-approved topical JAK inhibitor, ruxolitinib 1.5% cream represents a novel therapeutic topical agent for the treatment of AD. The objective of this review is to summarize the efficacy and safety of ruxolitinib cream in patients with AD based on the available evidence. Overall, ruxolitinib cream demonstrated high efficacy and a favorable safety profile for treating atopic dermatitis.
The psychosocial adaptation of patients with skin disease: a scoping review
AbstractAbstract Background Skin disease is a global public health problem that often has physiological, psychological and social impacts. However, it is not very clear how to adapt to these impacts, especially psychosocial adaptation of patients with skin disease. Methods We searched EMBASE, PubMed, CINAHL and PsycINFO from 2009 to 2018. The following themes were extracted from the included articles: the concepts, related factors, and interventions for psychosocial adaptation of patients with skin disease. Two reviewers independently screened and analyzed. Results From 2261 initial records, 69 studies were identified and analyzed. The concept of psychosocial adaptation in patients with skin disease was referred to under an assortment of descriptions. The related factors for psychosocial adaptation in patients with skin disease included the following: demographic factors (sex, age, education level, ethnicity, BMI, sleep quality, marital status, exercise amount, family history, the use of topical treatment only, personality and history of smoking); disease-related factors (disease severity, clinical symptoms, localization and duration); psychological factors (anxiety/depression, self-esteem, body image, stigma and suicidal ideation); and social factors (social support, social interaction, sexual life, economic burden and social acceptance). Despite being limited in quantity, several studies have clarified the benefits of adjuvant care in the form of cognitive behavioral training, educational training and self-help programs, all of which have become common methods for dealing with the psychosocial impacts. Conclusions Based on the previous literatures, we constructed a protocol of care model for psychosocial adaptation in patients with skin disease. It not only provided the direction for developing new instruments that could assess psychosocial adaptation statue, but also a basis for helping patients adjust to changes in skin disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
